Evaluation of a blood miRNA/mRNA signature to follow-up Lu-PRRT therapy for G1/G2 intestinal neuroendocrine tumors.

Front Endocrinol (Lausanne) · 2024 · PMC11212830 · PMID 38948517

Europe PMC DOI

hedged sentence

0.0521

closest p · 1.0× alpha

0.0521

boldest claim

The sentences

at the limit of significancep = 0.0521so close (0.05 < p ≤ 0.1)

Multivariate analysis showed that patient outcome could be predicted by miRNA/mRNA expression profiles after the first ( p = 0.0064) and the third LuPRRT ( p = 0.0105), whereas Ki-67 index was at the limit of significance ( p = 0.0521) ( Table 3 ).

also in 88 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.